Lymphocyte activation in silica-exposed workers

International Journal of Hygiene and Environmental Health

Volumn 217, Issue 4-5, 2014, Pages 586-591

  Rocha Parise, Michelle ^a   Santos, Leonilda M B ^a   Damoiseaux, Jan G M C ^b   Bagatin, Ericson ^a   Lido, Alessandro V ^a   Torello, Cristiane Okuda ^a   Cohen Tervaert, Jan W ^c,d   Queiroz, Mary L S ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d SINT FRANCISCUS GASTHUIS   (Netherlands)

Author keywords

Autoimmunity; Cytokines; Interleukin 2; Lymphocytes; Silica; Soluble IL 2 receptor alpha

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; POLLUTANT; SILICON DIOXIDE;

AGED; BLOOD; BRAZIL; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; FEMALE; HUMAN; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; OCCUPATIONAL EXPOSURE; POLLUTANT; TOXICITY;

AGED; BRAZIL; CELL PROLIFERATION; ENVIRONMENTAL POLLUTANTS; FEMALE; HUMANS; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; OCCUPATIONAL EXPOSURE; RECEPTORS, INTERLEUKIN-2; SILICON DIOXIDE;

EID: 84897073915     PISSN: 14384639     EISSN: 1618131X     Source Type: Journal    
DOI: 10.1016/j.ijheh.2013.11.002     Document Type: Article

References (47)

1. Cassel S.L., Eisenbarth S.C., Iyer S.S., Sadler J.J., Colegio O.R., Tephly L.A., Carter A.B., Rothman P.B., Flavell R.A., Sutterwala F.S. The Nalp3 inflammasome is essential for the development of silicosis. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:9035-9040.
2. Cavallo M.G., Pozzilli P., Thorpe R. Cytokines and autoimmunity. Clin. Exp. Immunol. 1994, 96:1-7.
3. Cohen Tervaert J.W., Stegeman C.A., Kallenberg C.G. Silicon exposure and vasculitis. Curr. Opin. Rheumatol. 1998, 10:12-17.
4. Conrad K., Mehlhorn J. Diagnostic and prognostic relevance of autoantibodies in uranium miners. Int. Arch. Allergy Immunol. 2000, 123:77-91.
5. Davis G.S., Pfeiffer L.M., Hemenway D.R. Persistent overexpression of interleukin-1beta and tumor necrosis factor-alpha in murine silicosis. J. Environ. Pathol. Toxicol. Oncol. 1998, 17:99-114.
6. Doll N.J., Stankus R.P., Hughes J., Weill H., Gupta R.C., Rodriguez M., Jones R.N., Alspaugh M.A., Salvaggio J.E. Immune complexes and autoantibodies in silicosis. J. Allergy Clin. Immunol. 1981, 68:281-285.
7. Dostert C., Petrilli V., Van Bruggen R., Steele C., Mossman B.T., Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008, 320:674-677.
8. Driscoll K.E., Carter J.M., Hassenbein D.G., Howard B. Cytokines and particle-induced inflammatory cell recruitment. Environ. Health Perspect. 1997, 105:1159-1164.
9. Feldmann M., Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu. Rev. Immunol. 2001, 19:163-196.
10. Gooding R., Riches P., Dadian G., Moore J., Gore M. Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2. Br. J. Cancer 1995, 72:452-455.
11. Grutters J.C., Fellrath J.M., Mulder L., Janssen R., Van den Bosch J.M., Velzen-Blad H. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation. Chest 2003, 124:186-195.
12. Hayashi H., Maeda M., Murakami S., Kumagai N., Chen Y., Hatayama T., Katoh M., Miyahara N., Yamamoto S., Yoshida Y., Nishimura Y., Kusaka M., Fujimoto W., Otsuki T. Soluble interleukin-2 receptor as an indicator of immunological disturbance found in silicosis patients. Int. J. Immunopathol. Pharmacol. 2009, 22:53-62.
13. Heaney M.L., Golde D.W. Soluble cytokine receptors. Blood 1996, 87:847-857.
14. Hornung V., Bauernfeind F., Halle A., Samstad E.O., Kono H., Rock K.L., Fitzgerald K.A., Latz E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 2008, 9:847-856.
15. Houssiau F.A., Lefebvre C., Vanden Berghe M., Lambert M., Devogelaer J.P., Renauld J.C. Serum interleukin 10 titres in systemic lupus erythematosus reflect disease activity. Lupus 1995, 4:393-395.
16. Huang C.-M., Chen C.-L. Elevated interleukin-10 levels correlate with disease activity in systemic lupus erythematosus. Mid. Taiwan J. Med. 2000, 5:37-42.
17. Huaux F. New developments in the understanding of immunology in silicosis. Curr. Opin. Allergy Clin. Immunol. 2007, 7:168-173.
18. International Labour Office Guidelines for the Use of ILO International Classification of Radiographs of Pneumoconiosis. Occupational Safety and Health Series No. 22 (Revised) 2000, ILO, Genebra.
19. Kim E.Y., Moudgil K.D. Regulation of autoimmune inflammation by pro-inflammatory cytokines. Immunol. Lett. 2008, 120:1-5.
20. King C., Ilic A., Koelsch K., Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004, 117:265-277.
21. Kitaoka S., Shiota G., Kawasaki H. Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C. Hepatogastroenterology 2003, 50:1569-1574.
22. Loughnan M.S., Sanderson C.J., Nossal G.J.V. Soluble interleukin 2 receptors are released from the cell surface of normal murine B lymphocytes stimulated with IL-5. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:3115-3119.
23. Murakami S. Soluble interleukin-2 receptor in cancer. Front. Biosci. 2004, 9:3085-3090.
24. Nurnberg W., Haas N., Schadendorf D., Czarnetzki B.M. Interleukin-6 expression in the skin of patients with lupus erythematosus. Exp. Dermatol. 1995, 4:52-57.
25. O'Shea J.J., Ma A., Lipsky P. Cytokines and autoimmunity. Nat. Rev. Immunol. 2002, 2:37-45.
26. Parks C.G., Conrad K., Cooper G.S. Occupational exposure to crystalline silica and autoimmune disease. Environ. Health Perspect. 1999, 107:793-802.
27. Peelen E., Damoiseaux J., Smolders J., Knippenberg S., Menheere P., Tervaert J.W., Hupperts R., Thewissen M. Th17 expansion in MS patients is counterbalanced by an expanded CD39+ regulatory T cell population during remission but not during relapse. J. Neuroimmunol. 2011, 240:97-103.
28. Peeters P.M., Perkins T.N., Wouters E.F.M., Mossman B.T., Reynaert N.L. Silica induces NLRP3 inflammasome activation in human lung epithelial cells. Part. Fibre Toxicol. 2013, 10:3.
29. Pernis B. Silica and the immune system. Acta Biomed. 2005, 2:38-44.
30. Rimal B., Greenberg A.K., Rom W.N. Basic pathogenetic mechanisms in silicosis: current understanding. Curr. Opin. Pulm. Med. 2005, 11:169-173.
31. Rocha M.C., Santos L.M.B., Bagatin E., Tervaert J.W.C., Damoiseaux J.G.M.C., Lido A.V., Longhini A.L., Torello C.O., Queiroz M.L.S. Genetic polymorphisms and surface expression of CTLA-4 and PD-1 on T cells of silica-exposed workers. Int. J. Hyg. Environ. Health 2012, 215:562-569.
32. Rose C.D., Fawcett P.T., Gibney K., Doughty R.A., Singsen B.H. Serial measurements of soluble interleukin 2 receptor levels (sIL2-R) in children with juvenile rheumatoid arthritis treated with oral methotrexate. Ann. Rheum. Dis. 1994, 53:471-474.
33. Rosenman K.D., Moore-Fuller M. Connective tissue diseases and silicosis. Am. J. Ind. Med. 1999, 35:375-381.
34. Rubin L.A., Jay G., Nelson D.L. The released interleukin 2 receptor binds interleukin 2 efficiently. J. Immunol. 1986, 137:3841-3844.
35. Rubin L.A., Kurman C.C., Fritz M.E., Biddison W.E., Boutin B., Yarchoan R., Nelson D.L. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J. Immunol. 1985, 135:3172-3177.
36. Rubin L.A., Nelson D.L. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann. Intern. Med. 1990, 113:619-627.
37. Santana A., Saxena B., Noble N.A., Gold L.I., Marshall B.C. Increased expression of transforming growth factor beta isoforms (beta 1, beta 2, beta 3) in bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 1995, 13:34-44.
38. Slavin R.E., Swendo J.L., Brandes D., Gonzalez-Vitale J.C., Osomio- Vargas A. Extrapulmonary silicosis: a clinical, morphological, and ultrastructural study. Hum. Pathol. 1985, 16:393-412.
39. Steenland K., Goldsmith D.F. Silica exposure and autoimmune diseases. Am. J. Ind. Med. 1995, 28:603-608.
40. Stegeman C.A., Cohen Tervaert J.W., Huitema M.G., Kallenberg C.G.M. Serum markers of T cell activation in relapses of Wegener's granulomatosis. Clin. Exp. Immunol. 1993, 91:415-420.
41. Subra J.F., Renier G., Reboul P., Tollis F., Boivinet R., Schwartz P., Chevailler A. Lymphopenia in occupational pulmonary silicosis with or without autoimmune disease. Clin. Exp. Immunol. 2001, 126:540-544.
42. Tesar V., Jirsa M., Masek Z., Bartunková J., Stejskalová A., Dostál C., Zabka J., Chábová V., Rysavá R. Soluble cytokinin receptors in renal vasculitis and lupus nephritis. Cas. Lek. Cesk. 1998, 137:271-275.
43. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 2003, 3:133-146.
44. Ueki A., Yamaguchi M., Ueki H., Watanabe Y., Ohsawa G., Kinugawa K., Kawakami Y., Hyodoh F. Polyclonal human T-cell activation by silicate in vitro. Immunology 1994, 82:332-335.
45. Wahl S.M., McCartney-Francis N., Mergenhagen S.E. Inflammatory and immunomodulatory roles of TGF-beta. Immunol. Today 1989, 10:258-261.
46. Witkowska A.M. On the role of sIL-2R measurements in rheumatoid arthritis and cancers. Mediators Inflamm. 2005, 3:121-130.
47. Wolf R.E., Baethge B.A. Interleukin-1 alpha, interleukin-2, and soluble interleukin-2 receptors in polymyositis. Arthritis Rheum. 1990, 33:1007-1014.